TLR9 and autoimmune disease: Recent advancements include the discovery of small-molecular antagonists, such as 7f, which exhibits strong on-target potency and selectivity against TLR7 and TLR9, demonstrating efficacy in the preclinical models of autoimmune diseases by oral administration [66].